Biosensorix is a privately held diagnostic company that provides affordable tools enabling fast and accurate life-saving decisions. The company is focused on bringing quantitation to rapid point-of-care testing, allowing earlier and precise treatment that will benefit patients in developing countries and worldwide. The initial technologies target dengue diagnosis and will extend to disease marker detection areas where quantitation is vital and currently unmet. Established in November 2015, Biosensorix is a spin-off from the collaboration between Ben Gurion University of the Negev (Israel) and Nanyang Technological University (Singapore) under the NEW CREATE program in Singapore. The impact and platform success led to support from National Research Foundation (NRF), Singapore-MIT Alliance for Research and Technology (SMART), and SPRING Singapore. Biosensorix is committed to saving lives and healthcare dollars, one patient at a time.